CD8A and neoplasm: In particular, the Immunoscore, which is obtained from the densities of CD3+ and CD8+ T-cells in the tumor center and invasive margin, has been reported to hold superior and independent prognostic value over the traditional TNM system in patients with stage II–III CRC [5, 6].